Active ingredient: Reboxetine
Note about medicines names
Most medicines have two names: the active ingredient and the brand name. The active ingredient is the chemical in the medicine that makes it work. The brand name is the name given to the medicine by its manufacturer. There may be several brands that contain the same active ingredient. This website uses active ingredient names (e.g. amoxycillin), with brand names in brackets and with a capital letter (e.g. Amoxil). We also discuss medicines in groups or ‘classes’ when their effects or actions are very similar.
What is reboxetine?
Reboxetine is a type of antidepressant called a norepinephrine reuptake inhibitor (NRI).
Find out more about
- What reboxetine does and how effective it is
- Who reboxetine is for and who should be cautious
- Side effects of reboxetine
- Interactions with reboxetine
- Brands of reboxetine
If you are starting reboxetine, see 10 things you should know about antidepressants.
For more information
- Starting, switching and stopping antidepressants
- Managing side effects of antidepressants
- Psychological therapies
The consumer medicine information (CMI) for your brand of reboxetine is available from our website or a pharmacist. The CMI includes:
- how to take this medicine
- what to do if you forget to take it
- if you take too much (overdose)
- things you must and must not do while taking this medicine
- signs of severe reactions and what to do.
- Australian Medicines Handbook 2015. Adelaide: Australian Medicines Handbook Pty Ltd; 2015 January. [Online].
- Psychotropic Expert Group. Therapeutic Guidelines: Psychotropic, Version 6. In: eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines Limited; 2008.
- Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743–56. [PubMed]
- Pfizer Australia Pty Ltd. Edronax consumer medicine information. August 2011. (Accessed 22 March 2012).
- Pfizer Australia Pty Ltd. Edronax product information. 1 August 2011. (Accessed 22 March 2012).
- National Collaborating Centre for Mental Health (UK). Depression: the treatment and management of depression in adults (updated edition). Leicester (UK): British Psychological Society, 2010. [PubMed].
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58. [PubMed]
- Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737. [PubMed]